A team led by Oxford University has identified genes that make certain children more susceptible to invasive bacterial infections by performing a large genome-wide association study in African children. Dr Anna Rautanen from Adrian Hill's research group at the Wellcome Trust Centre for Human Genetics, said: 'Critically, the genetic variants we have identified carry a doubled risk of developing bacteraemia when infected with the Streptococcus pneumoniae bacteria. This discovery therefore provides clues in the pressing search for new ways to target the disease.'
Red tape is hampering scientists from developing groundbreaking GM vaccines, it is claimed. Adrian Hill, of Oxford University, said that this was holding back research. “Because the vaccine is technically a GM organism, if we’re going to vaccinate someone in our clinic we need special permission, not to protect the person from the dangers of the vaccine but to protect from the potential risks of that microbe getting out and contaminating the environment,” he said. This was despite the fact, he added, that it would not survive.
Can we control all-cause meningococcal disease in Europe? Clin Microbiol Infect. Article
The Antibody Response Following a Booster with Either a 10- Or 13-Valent Pneumococcal Conjugate Vaccine in Toddlers Primed with a 13-Valent Pneumococcal Conjugate Vaccine in Early Infancy. Pediatr Infect Dis J. Article
Dr Man-Wah Tan: Harnessing the immune system: antibodies as therapeutics against viral and bacterial infections, 31/May/2016 14:00
Clinical trials are an essential part of vaccine development, and our volunteers play a critical role in our studies.
If you would like to find out more about paid clinical trials, and what is involved in participating, please go to our Recruiting Trials page to see which trials are currently recruiting.